ADORING 1
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Sanofi’s amlitelimab shows positive results in atopic dermatitis
Newly released study data shows consistent reductions in disease severity
Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms
Some patients found the treatment reduced itch and sleep disturbance within just two days
Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study
The inflammatory skin condition affects over 26 million people in the US
Eli Lilly/Almirall’s Ebglyss shows promise in atopic dermatitis patients with darker skin tones
The inflammatory skin condition occurs in approximately 7.3% of adults in the US
Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones
These are the first clinical study results for the drug in a large population of patients with darker skin tones
Galderma shares positive two-year results for Nemluvio in atopic dermatitis
The chronic inflammatory skin disease affects more than 230 million people worldwide
Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis
The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide
Organon shares positive long-term results for Vtama cream in atopic dermatitis
The common inflammatory skin disease affects more than 26 million people in the US alone
MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases
EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha
Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn
Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients